183 related articles for article (PubMed ID: 20720054)
1. Reproducibility of 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET tumor volume measurements.
Hatt M; Cheze-Le Rest C; Aboagye EO; Kenny LM; Rosso L; Turkheimer FE; Albarghach NM; Metges JP; Pradier O; Visvikis D
J Nucl Med; 2010 Sep; 51(9):1368-76. PubMed ID: 20720054
[TBL] [Abstract][Full Text] [Related]
2. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
5. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R
J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology.
Hatt M; Visvikis D; Albarghach NM; Tixier F; Pradier O; Cheze-le Rest C
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1191-202. PubMed ID: 21365252
[TBL] [Abstract][Full Text] [Related]
7. 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
Chen H; Li Y; Wu H; Sun L; Lin Q; Zhao L; An H
Strahlenther Onkol; 2015 Feb; 191(2):141-52. PubMed ID: 25163419
[TBL] [Abstract][Full Text] [Related]
8. Comparison of characteristics of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET during staging of esophageal squamous cell carcinoma.
Ma C; Li D; Yin Y; Cao J
Nucl Med Commun; 2015 Dec; 36(12):1181-6. PubMed ID: 26367213
[TBL] [Abstract][Full Text] [Related]
9. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.
Han D; Yu J; Yu Y; Zhang G; Zhong X; Lu J; Yin Y; Fu Z; Mu D; Zhang B; He W; Huo Z; Liu X; Kong L; Zhao S; Sun X
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1235-41. PubMed ID: 19910143
[TBL] [Abstract][Full Text] [Related]
10. Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.
Heijmen L; de Geus-Oei LF; de Wilt JH; Visvikis D; Hatt M; Visser EP; Bussink J; Punt CJ; Oyen WJ; van Laarhoven HW
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1858-67. PubMed ID: 22945372
[TBL] [Abstract][Full Text] [Related]
11. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
12. Comparative assessment of segmentation algorithms for tumor delineation on a test-retest [(11)C]choline dataset.
Tomasi G; Shepherd T; Turkheimer F; Visvikis D; Aboagye E
Med Phys; 2012 Dec; 39(12):7571-9. PubMed ID: 23231305
[TBL] [Abstract][Full Text] [Related]
13. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
14. Comparison of
Mori M; Fujioka T; Ichikawa R; Inomata R; Katsuta L; Yashima Y; Yamaga E; Tsuchiya J; Hayashi K; Kumaki Y; Oda G; Nakagawa T; Onishi I; Kubota K; Tateishi U
Tomography; 2022 Oct; 8(5):2533-2546. PubMed ID: 36287810
[TBL] [Abstract][Full Text] [Related]
15. Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer.
Hatt M; Le Pogam A; Visvikis D; Pradier O; Cheze Le Rest C
J Nucl Med; 2012 Jan; 53(1):12-20. PubMed ID: 22213819
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
17. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.
Kameyama R; Yamamoto Y; Izuishi K; Takebayashi R; Hagiike M; Murota M; Kaji M; Haba R; Nishiyama Y
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):382-8. PubMed ID: 18985344
[TBL] [Abstract][Full Text] [Related]
18. Repeatability of
Lodge MA; Holdhoff M; Leal JP; Bag AK; Nabors LB; Mintz A; Lesser GJ; Mankoff DA; Desai AS; Mountz JM; Lieberman FS; Fisher JD; Desideri S; Ye X; Grossman SA; Schiff D; Wahl RL
J Nucl Med; 2017 Mar; 58(3):393-398. PubMed ID: 27688473
[TBL] [Abstract][Full Text] [Related]
19. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
Yamane T; Takaoka A; Kita M; Imai Y; Senda M
Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
[TBL] [Abstract][Full Text] [Related]
20. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
